Dr Solange Peters describes MET signaling pathway in cancer. Explanation of the pathway features is enhanced visually by animated illustration of the signaling cascade. This material is part of the forthcoming and comprehensive ESMO V-Learning module on targeting MET with an emphasis on non-small cell lung cancer.
Targeting MET with an emphasis on NSCLC
MET is the only known receptor for hepatocyte growth factor (HGF). Activation of the MET receptor by HGF binding triggers a large, multistep, tightly regulated and intricated signal transduction cascade. These signalling events also culminate in initiating almost all cellular processes defining the malignant phenotype.
The goal of this V-learning module is to provide a scientific overview of the multidomain structure of MET and HGF, milestones in MET and HGF discoveries, to show signalling cascade and subsequently triggered processes in an animated model to enhance understanding, to provide an update on dysregulation of the MET signalling pathway which occurs in a wide range of human cancers, to review selected MET inhibitors and their inhibitory targets in the MET pathway, and provide a scientific rationale on data from recent clinical studies in different tumour types, but with a special emphasis on non-small cell lung cancer.